These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 9770117

  • 1. Pre-clinical development of farnesyltransferase inhibitors.
    Lobell RB, Kohl NE.
    Cancer Metastasis Rev; 1998 Jun; 17(2):203-10. PubMed ID: 9770117
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 3. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 4. RAS inhibitors: potential for cancer therapeutics.
    Kloog Y, Cox AD.
    Mol Med Today; 2000 Oct 27; 6(10):398-402. PubMed ID: 11006529
    [Abstract] [Full Text] [Related]

  • 5. Farnesyltransferase inhibitors.
    Sebti SM, Adjei AA.
    Semin Oncol; 2004 Feb 27; 31(1 Suppl 1):28-39. PubMed ID: 14981578
    [Abstract] [Full Text] [Related]

  • 6. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA, Chen Z, Diehl RE, Conner MW, Chen HY, Trumbauer ME, Gopal-Truter S, Seeburger G, Bhimnathwala H, Abrams MT, Davide JP, Ellis MS, Gibbs JB, Greenberg I, Koblan KS, Kral AM, Liu D, Lobell RB, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Senderak ET, Oliff A, Kohl NE.
    Cancer Res; 2000 May 15; 60(10):2680-8. PubMed ID: 10825141
    [Abstract] [Full Text] [Related]

  • 7. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
    Cox AD.
    Drugs; 2001 May 15; 61(6):723-32. PubMed ID: 11398905
    [Abstract] [Full Text] [Related]

  • 8. Evolving therapies: farnesyltransferase inhibitors.
    Purcell WT, Donehower RC.
    Curr Oncol Rep; 2002 Jan 15; 4(1):29-36. PubMed ID: 11734111
    [Abstract] [Full Text] [Related]

  • 9. Farnesyltransferase inhibitors.
    Hahn SM, Bernhard E, McKenna WG.
    Semin Oncol; 2001 Oct 15; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [Abstract] [Full Text] [Related]

  • 10. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
    Rose WC, Lee FY, Fairchild CR, Lynch M, Monticello T, Kramer RA, Manne V.
    Cancer Res; 2001 Oct 15; 61(20):7507-17. PubMed ID: 11606387
    [Abstract] [Full Text] [Related]

  • 11. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
    Gibbs JB, Oliff A.
    Annu Rev Pharmacol Toxicol; 1997 Oct 15; 37():143-66. PubMed ID: 9131250
    [Abstract] [Full Text] [Related]

  • 12. Farnesyltransferase inhibitors. Preclinical development.
    Kohl NE.
    Ann N Y Acad Sci; 1999 Oct 15; 886():91-102. PubMed ID: 10667207
    [Abstract] [Full Text] [Related]

  • 13. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J, Pradines A, Favre G.
    Cancer Lett; 2004 Apr 08; 206(2):159-67. PubMed ID: 15013521
    [Abstract] [Full Text] [Related]

  • 14. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J, Blaskovich MA, Sebti SM, Hamilton AD.
    Prog Cell Cycle Res; 2003 Apr 08; 5():211-7. PubMed ID: 14593715
    [Abstract] [Full Text] [Related]

  • 15. Farnesyltransferase inhibitors and anti-Ras therapy.
    Gibbs JB, Kohl NE, Koblan KS, Omer CA, Sepp-Lorenzino L, Rosen N, Anthony NJ, Conner MW, deSolms SJ, Williams TM, Graham SL, Hartman GD, Oliff A.
    Breast Cancer Res Treat; 1996 Apr 08; 38(1):75-83. PubMed ID: 8825125
    [Abstract] [Full Text] [Related]

  • 16. [Development of farsenyl transferase inhibitors as anticancer agents].
    Cestac P, Doisneau-Sixou S, Favre G.
    Ann Pharm Fr; 2005 Jan 08; 63(1):76-84. PubMed ID: 15803104
    [Abstract] [Full Text] [Related]

  • 17. Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth.
    Omer CA, Anthony NJ, Buser-Doepner CA, Burkhardt AL, deSolms SJ, Dinsmore CJ, Gibbs JB, Hartman GD, Koblan KS, Lobell RB, Oliff A, Williams TM, Kohl NE.
    Biofactors; 1997 Jan 08; 6(3):359-66. PubMed ID: 9288406
    [Abstract] [Full Text] [Related]

  • 18. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
    Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J.
    Cell Mol Life Sci; 2001 Oct 08; 58(11):1636-49. PubMed ID: 11706990
    [Abstract] [Full Text] [Related]

  • 19. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K, Hamilton AD, Sebti SM.
    Curr Opin Investig Drugs; 2003 Dec 08; 4(12):1428-35. PubMed ID: 14763128
    [Abstract] [Full Text] [Related]

  • 20. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF, Prendergast GC.
    Oncogene; 1998 Sep 17; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.